Scinai Immunotherapeutics (SCNI) Corporate presentation summary

Strategic focus and business model

• Pursues a dual business model: innovative NanoAb biologics for inflammation and immunology and boutique CDMO services for revenue generation.

• Lead asset targets the large, underserved psoriasis market, aiming for localized efficacy with fewer systemic side effects.

• Pipeline includes first-in-class mAb for rare skin disorders and multiple NanoAb candidates for large unmet needs.

• Collaborations with Max Planck Society and UMG provide scientific and clinical advantages.

• Strategic financing options, including non-dilutive funding and grants, are being pursued.

NanoAb platform and advantages

• NanoAbs are small, camelid-derived VHH antibodies with superior specificity, stability, and manufacturability compared to mAbs.

• Enable faster, lower-cost production and higher API yield per gram than traditional mAbs.

• Offer multiple administration routes, longer shelf life, and fewer contraindications.

• Validated by commercial precedents and strong demand for new therapies in underserved populations.

Pipeline and clinical progress

• Lead anti-IL-17 NanoAb for psoriasis completed in-vivo proof-of-concept; clinical trial planned for 2027.

• Pipeline includes assets for pemphigus, SJS/TEN, and other inflammatory and TH2 diseases.

• Intradermal administration designed for convenience, high efficacy, and local targeting.

• Ex-vivo and in-vivo studies show NanoAb blocks IL-17 isoforms and outperforms standard of care.

• No observed adverse effects and durable therapeutic response in preclinical models.